Clinical Trial: EZM0414

Trial Status: Open
Disease Types: Lymphoma, Multiple Myeloma
Trial ID EZM0414
Sponsor ID SET-101

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Principal Investigator
Mitul Gandhi, MD


Fairfax Office

Learn More About This Trial
Other Relevant Trials
Trial ID 21552
Sponsor ID RGX-104-001

“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”

Trial ID 21273
Sponsor ID GS-US-558-5915

“GS-US-558-5915: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma”

Principal Investigator
Mitul Gandhi, MD
3 Locations